Canada Life’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

Canada Life’s Portfolio BSX.PRA Stock Details BSX.PRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,600	Closed	-$631K	–	2322
2023 Q1	$631K	Sell	5,600 -3,800	-40%	-$437K	﹤0.01%	1646
2022 Q4	$1.08M	Buy	9,400 +500	+6%	+$55.1K	﹤0.01%	1491
2022 Q3	$920K	Buy	8,900 +1,100	+14%	+$116K	﹤0.01%	1519
2022 Q2	$780K	Hold	7,800	–	–	﹤0.01%	1560
2022 Q1	$907K	Hold	7,800	–	–	﹤0.01%	1551
2021 Q4	$880K	Buy	+7,800	New	+$890K	﹤0.01%	1566
2020 Q4	–	Sell	-2,500	Closed	-$278K	–	2666
2020 Q3	$278K	Hold	2,500	–	–	﹤0.01%	1821
2020 Q2	$261K	Buy	+2,500	New	+$268K	﹤0.01%	1843

Other funds holding BSX.PRA

LTI

Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Canada Life's BSX.PRA Position: Q2 2023 in Review

Canada Life sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q2 2023, closing a stake of 5,600 shares — an estimated $631K sold.

Canada Life first reported a position in BSX.PRA in Q2 2020 and held it in 8 quarters. The position peaked at $1.08M in Q4 2022. 1 fund tracked by Wall St. Rank holds BSX.PRA as of Q2 2023.

Canada Life reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q2 2023 after selling out during the quarter.
Canada Life sold 5,600 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q2 2023, an estimated $631K.
Canada Life first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q2 2020 and held it in 8 quarters.
Canada Life's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $1.08M in Q4 2022.
1 fund tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q2 2023.

Based on Canada Life's 13F filing for Q2 2023, filed 10 Aug 2023.